Drug Development

Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

27th April 2016

Novartis announced that the US Food and Drug Administration (FDA) has granted three Breakthrough Therapy Designations for Ilaris® (canakinumab) to...

AbbVie, University of Chicago team collaborative on cancer innovation efforts

by Yuvraj_pawp

20th April 2016

The University of Chicago and AbbVie a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve...

Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA in Classical Hodgkin Lymphoma (cHL)

by Yuvraj_pawp

18th April 2016

Merck, known as MSD outside the United States and Canada, announced that the U.S. FDA has granted Breakthrough Therapy Designation...

Advancing Patient Recruitment & Engagement in Clinical Trials

by Yuvraj_pawp

9th April 2016

This whitepaper highlights some of the most advanced companies in their innovative approaches to trial recruitment. Witness first-hand 5 case...

Inovio Signs Collaborative Research Agreements

by Yuvraj_pawp

18th March 2016

Inovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and VaccinesNew Agreement Follows Dr. David B. Weiner’s Move...

AstraZeneca’s potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation

by Yuvraj_pawp

18th March 2016

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA)...

Orexigen and Takeda Jointly Announce Orexigen’s Acquisition of All Rights to CONTRAVE® in United States

by Yuvraj_pawp

18th March 2016

Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets Takeda Moves to Strengthen Focus on Recent Launches Orexigen...